WO2022256800A3 - Human spermine oxidase crystal and uses thereof - Google Patents

Human spermine oxidase crystal and uses thereof Download PDF

Info

Publication number
WO2022256800A3
WO2022256800A3 PCT/US2022/072667 US2022072667W WO2022256800A3 WO 2022256800 A3 WO2022256800 A3 WO 2022256800A3 US 2022072667 W US2022072667 W US 2022072667W WO 2022256800 A3 WO2022256800 A3 WO 2022256800A3
Authority
WO
WIPO (PCT)
Prior art keywords
spermine oxidase
human
human spermine
deletion
substitution
Prior art date
Application number
PCT/US2022/072667
Other languages
French (fr)
Other versions
WO2022256800A2 (en
WO2022256800A9 (en
Inventor
Antonietta IMPAGLIAZZO
Carolina Martinez LAMENCA
Josep Llaveria Cros
Lichao FANG
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of WO2022256800A2 publication Critical patent/WO2022256800A2/en
Publication of WO2022256800A3 publication Critical patent/WO2022256800A3/en
Publication of WO2022256800A9 publication Critical patent/WO2022256800A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0032—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with oxygen as acceptor (1.5.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/03—Oxidoreductases acting on the CH-NH group of donors (1.5) with oxygen as acceptor (1.5.3)
    • C12Y105/03016—Spermine oxidase (1.5.3.16)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A human spermine oxidase polypeptide comprises a wild-type amino acid sequence that is modified by the deletion of one or more amino acids in the region of random coil, the substitution of a surface exposed charged amino acid, the deletion and/or substitution of amino acids at the N-terminus, and/or the deletion and/or substitution of amino acids at the C- terminus. The human spermine oxidase polypeptide may be expressed, purified, and crystallized for use in determining a three-dimensional representation of human spermine oxidase. Potential inhibitors of the human spermine oxidase may be identified by using the three-dimensional representation.
PCT/US2022/072667 2021-06-04 2022-06-01 Human spermine oxidase crystal and uses thereof WO2022256800A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163202294P 2021-06-04 2021-06-04
US63/202,294 2021-06-04
EP21187093.6 2021-07-22
EP21187093 2021-07-22

Publications (3)

Publication Number Publication Date
WO2022256800A2 WO2022256800A2 (en) 2022-12-08
WO2022256800A3 true WO2022256800A3 (en) 2023-03-16
WO2022256800A9 WO2022256800A9 (en) 2023-08-17

Family

ID=84323600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/072667 WO2022256800A2 (en) 2021-06-04 2022-06-01 Human spermine oxidase crystal and uses thereof

Country Status (1)

Country Link
WO (1) WO2022256800A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2009026172A2 (en) * 2007-08-17 2009-02-26 The Regents Of The University Of California New approach for designing diabetes drugs
WO2020016800A1 (en) * 2018-07-17 2020-01-23 Nib Biotec S.R.L. Method for the in vitro diagnosis of prostate cancer by means of urinary biomarkers
CN110590785B (en) * 2019-09-23 2021-02-02 武汉大学 Aminothiazole compound, preparation method thereof and application of aminothiazole compound in resisting enterovirus 71

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2009026172A2 (en) * 2007-08-17 2009-02-26 The Regents Of The University Of California New approach for designing diabetes drugs
WO2020016800A1 (en) * 2018-07-17 2020-01-23 Nib Biotec S.R.L. Method for the in vitro diagnosis of prostate cancer by means of urinary biomarkers
CN110590785B (en) * 2019-09-23 2021-02-02 武汉大学 Aminothiazole compound, preparation method thereof and application of aminothiazole compound in resisting enterovirus 71

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 19 July 2004 (2004-07-19), "RecName: Full=Spermine oxidase; EC=1.5.3.16 {ECO:0000269|PubMed:11454677, ECO:0000269|PubMed:12398765}; AltName: Full=Polyamine oxidase 1; Short=PAO-1; Short=PAOh1;", XP002808509, retrieved from EBI accession no. UNIPROT:Q9NWM0 Database accession no. Q9NWM0 *
DEREWENDA ZYGMUNT S.: "Application of protein engineering to enhance crystallizability and improve crystal properties", ACTA CRYSTALLOGRAPHICA SECTION D, vol. 66, no. 5, 1 May 2010 (2010-05-01), pages 604 - 615, XP055893360, ISSN: 0907-4449, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089013/pdf/d-66-00604.pdf> DOI: 10.1107/S090744491000644X *
DIAZ ELSIE ET AL: "Structure of human spermine oxidase in complex with a highly selective allosteric inhibitor", COMMUNICATIONS BIOLOGY, vol. 5, no. 1, 5 August 2022 (2022-08-05), XP093016742, Retrieved from the Internet <URL:https://www.nature.com/articles/s42003-022-03735-9> DOI: 10.1038/s42003-022-03735-9 *
DURANTON B ET AL: "Cytotoxic effects of the polyamine oxidase inactivator MDL 72527 to two human colon carcinoma cell lines SW480 and SW620", CELL BIOLOGY AND TOXICOLOGY, SPRINGER NETHERLANDS, NL, vol. 18, no. 6, 1 December 2002 (2002-12-01), XP037832585, ISSN: 0742-2091, DOI: 10.1023/A:1020863506170 *
MCINNES ET AL: "Virtual screening strategies in drug discovery", CURRENT OPINION IN CHEMICAL BIOLOGY, CURRENT BIOLOGY LTD, LONDON, GB, vol. 11, no. 5, 22 October 2007 (2007-10-22), pages 494 - 502, XP022323960, ISSN: 1367-5931, DOI: 10.1016/J.CBPA.2007.08.033 *
MORIYA SHUN-SUKE ET AL: "Development of Irreversible Inactivators of Spermine Oxidase and <i>N</i><sup>1</sup>-Acetylpolyamine Oxidase", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 37, no. 3, 1 March 2014 (2014-03-01), JP, pages 475 - 480, XP055893276, ISSN: 0918-6158, DOI: 10.1248/bpb.b13-00913 *
MURRAY STEWART TRACY ET AL: "Polyamine catabolism and oxidative damage", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 293, no. 48, 17 October 2018 (2018-10-17), US, pages 18736 - 18745, XP055893397, ISSN: 0021-9258, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0021925820311819/pdfft?md5=067fdd079e27dd1243edb2bb87ea90ee&pid=1-s2.0-S0021925820311819-main.pdf> DOI: 10.1074/jbc.TM118.003337 *
MURRAY-STEWART ET AL: "TARGETING POLYAMINE METABOLISM FOR CANCER THERAPY AND PREVENTION", BIOCHEMICAL JOURNAL,, vol. 473, 1 January 2016 (2016-01-01), pages 2937 - 2953, XP002775862, DOI: 10.1042/BCJ20160383 *
SJÖGREN TOVE ET AL: "The Structure of Murine N 1 -Acetylspermine Oxidase Reveals Molecular Details of Vertebrate Polyamine Catabolism", BIOCHEMISTRY, vol. 56, no. 3, 12 January 2017 (2017-01-12), pages 458 - 467, XP093017479, ISSN: 0006-2960, DOI: 10.1021/acs.biochem.6b01140 *
SUN LIDAN ET AL: "Discovery and antitumor evaluation of novel inhibitors of spermine oxidase", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 34, no. 1, 1 January 2019 (2019-01-01), GB, pages 1140 - 1151, XP093016764, ISSN: 1475-6366, Retrieved from the Internet <URL:https://tandfonline.com/doi/pdf/10.1080/14756366.2019.1621863> DOI: 10.1080/14756366.2019.1621863 *

Also Published As

Publication number Publication date
WO2022256800A2 (en) 2022-12-08
WO2022256800A9 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
JP2019531316A5 (en)
Kutzbach et al. Preparation and general properties of crystalline penicillin acylase from Escherichia coli ATCC 11 105
JP2021052784A5 (en)
CY1115142T1 (en) USE OF PATHIDES PRODUCERS OF CATHELISIDINE LL-37 FOR TREATMENT OF YEARS
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
PE20120358A1 (en) FGF21 MUTANTS AND USES OF THEM
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ATE462000T1 (en) METHOD FOR PRODUCING L-ARGININE, L-ORNITHINE OR L-CITRULLINE
MX2010002001A (en) Cdca1 peptide and pharmaceutical agent comprising the same.
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
WO2018116165A3 (en) Therapeutically active complexes
AR120891A1 (en) MUTANT RSV F PROTEIN AND ITS USE
MX2021002295A (en) Recombinant protein variants.
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
WO2005068632A8 (en) EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED Ep-CAM-SPECIFIC CTL AND USE OF THE SAME
WO2022256800A3 (en) Human spermine oxidase crystal and uses thereof
MX2021012032A (en) Compositions and methods for stabilizing protein-containing formulations.
AU2002310474A1 (en) Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
BR0309491A (en) Vaccine composition, immunogenic composition, use of an e7 protein and neutralizing antibodies
DK1913020T3 (en) Immunogenic constructs
WO2019219903A3 (en) Mutant lipase and use thereof
MX2010005816A (en) Stat3 epitope peptides.
CO2020016749A2 (en) Novel protein with anti-inflammatory properties

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22786665

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE